Ecopa 2018

Registration

Opening Keynote

Modeling Human pathogenesis using novel in vitro and in silico methods
Robert BAROUKI (INSERM - UMR-S 747)

Keynote 1:
From Organ-on-a-Chip Tools Towards Patients on Chips - Enforcing a Paradigm Shift in Drug Development
U. MARX (TissUse, GmbH)

Oral presentations 1.1
Prion diseases: toward further reduction of animal experimentation
M. MOUDJOU (INRA)

Oral presentations 1.2
Drosophila: an alternative model for the modeling of human pathologies and the search for new therapies
H. TRICOIRE (Paris-Diderot University - UMR 8251 Unité BFA)

Oral presentations 1.3
Genotoxic and carcinogenic potential of 160 mycotoxins in human cells
M. AUDEBERT (INRA, UMR1331 Toxalim)

Oral presentations 1.4
Zebrafish larva: a reliable alternative of mammalian model to evaluate the impact of environmental contaminants on the mechanisms of liver disease progression
M. IMRAN (INSERM - IRSET - UMR S 1085)

Keynote 2:
Organoids, organs-on-chip, 3D bioprinting in a 3R context
X. GIDROL (CEA)

Oral presentations 2.1
Innovative 3D culture model of human hepatocytes with large potential applications
S. LANGOUET-PRIGENT (INSERM)

Oral presentations 2.2
HepatoPearls: New generation of liver-mimicking spheroids
N. DIANAT (CYPRIO)

Oral presentations 2.3
Development of a novel in vitro aerosol exposure system: the independent holistic air-liquid aerosol exposure system (inhales)
S. STEINER (Philip Morris International R&D)

Oral presentations 2.4
Neurospheres for Species-Specific, Medium-Throughput Analyses of Developmental Neurotoxicity (DNT) Evaluation
E. FRITSCHE (IUF - Leibniz Research Institute for Environmental Medicine)

Keynote 3:
Input of proteomic analyses for understanding cellular responses to nanoparticles: toward mechanistic data and evidence for cross-toxic effects
T. RABILLOUD (CEA)

Oral presentations 3.1
High throughput techniques for a predictive toxicology
R. GRALL (CEA)

Oral presentations 3.2
Role of Persistant Organics Pollutants and adipocytes in the acquisition of a metastatic potential and of chemoresistance in breast cancer
C. TOMKIEWICZ-RAULET or M. KOUAL (INSERM)

Oral presentations 3.3
Modern science for 3Rs alternative approaches and better quality control of human vaccines
S. UHLRICH (SANOFI PASTEUR)

Oral presentations 3.4
Development of SENS-IS, an in vitro assay to measure skin sensitization potency of chemicals
H. GROUX (IMMUNOSEARCH)